Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 120 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $122.41, for a total value of $14,689.20. Following the completion of the sale, the senior vice president now directly owns 31,995 shares in the company, valued at $3,916,507.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 125.51 on Thursday. Alexion Pharmaceuticals Inc. has a 52-week low of $110.56 and a 52-week high of $193.45. The firm has a market capitalization of $28.15 billion, a PE ratio of 315.35 and a beta of 1.33. The stock’s 50 day moving average price is $128.24 and its 200 day moving average price is $134.99.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing the consensus estimate of $1.17 by $0.04. The firm earned $753 million during the quarter, compared to analysts’ expectations of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the business posted $1.44 earnings per share. Analysts expect that Alexion Pharmaceuticals Inc. will post $4.67 earnings per share for the current year.
Several analysts have commented on the company. Brean Capital assumed coverage on Alexion Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $221.00 price objective on the stock. Vetr raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 price objective on the stock in a report on Thursday, September 29th. Zacks Investment Research raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 27th. Leerink Swann lifted their price target on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the stock an “outperform” rating in a research note on Monday, September 26th. Finally, Jefferies Group lowered their price target on Alexion Pharmaceuticals from $140.00 to $120.00 and set a “hold” rating on the stock in a research note on Friday, September 23rd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $178.32.
Hedge funds and other institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new position in shares of Alexion Pharmaceuticals during the first quarter valued at $114,000. NEXT Financial Group Inc raised its position in shares of Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 440 shares during the period. Bellwether Investment Group LLC purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at $172,000. Charlemagne Capital Ltd. purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at $191,000. Finally, Evercore Wealth Management LLC raised its position in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 83 shares during the period. 96.34% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.